Abstract
Melanomas are associated with several hereditary conditions. We present a large family with several family members affected with primary melanomas and dysplastic nevi as well as thyroid cancer and other malignant tumors. Clinical work-up did not reveal a mutation in any of the genes usually considered with evaluation for predisposition to melanoma (BRCA1/2, CDKN2A, CDK4, PTEN, TP53). Whole exome sequencing of five affected family members showed a new variant in POT1. POT1 is associated with the telomere shelterin complex that regulates telomere protection and telomerase access. Germline mutations in POT1 were recently shown to be associated with hereditary predisposition to melanoma. Our findings support a role of POT1 germline mutations in cancer predisposition beyond melanoma development, suggesting a broader phenotype of the POT1-associated tumor predisposition syndrome that might also include thyroid cancer as well as possibly other malignant tumors.
Similar content being viewed by others
References
Read J, Wadt KA, Hayward NK (2016) Melanoma genetics. J Med Genet 53(1):1–14. doi:10.1136/jmedgenet-2015-103150
Hu HH, Benfodda M, Dumaz N et al (2014) A large French case-control study emphasizes the role of rare Mc1R variants in melanoma risk. Biomed Res Int. doi:10.1155/2014/925716
Pasquali E, Garcia-Borron JC, Fargnoli MC et al (2015) MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer 136(3):618–631. doi:10.1002/ijc.29018
Bertolotto C, Lesueur F, Giuliano S et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94–98. doi:10.1038/nature10539
Yokoyama S, Woods SL, Boyle GM et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375):99–103. doi:10.1038/nature10630
Goldstein AM, Chan M, Harland M et al (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66(20):9818–9828. doi:10.1158/0008-5472.CAN-06-0494
Hussussian CJ, Struewing JP, Goldstein AM et al (1994) Germline p16 mutations in familial melanoma. Nat Genet 8(1):15–21. doi:10.1038/ng0994-15
Zuo L, Weger J, Yang Q et al (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12(1):97–99. doi:10.1038/ng0196-97
Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022–1025. doi:10.1038/ng.912
Wiesner T, Obenauf AC, Murali R et al (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018–1021. doi:10.1038/ng.910
Aoude LG, Pritchard AL, Robles-Espinoza CD et al (2015) Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst. doi:10.1093/jnci/dju408
Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961. doi:10.1126/science.1230062
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959. doi:10.1126/science.1229259
Robles-Espinoza CD, Harland M, Ramsay AJ et al (2014) POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 46(5):478–481. doi:10.1038/ng.2947
Shi J, Yang XR, Ballew B et al (2014) Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet 46(5):482–486. doi:10.1038/ng.2941
Chen R, Im H, Snyder M (2015) Whole-exome enrichment with the Roche NimbleGen SeqCap EZ exome library SR platform. Cold Spring Harb Protoc 2015(7): 634–641. doi:10.1101/pdb.prot084855
Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25(14):1754–1760. doi:10.1093/bioinformatics/btp324
Tischler G, Durbin, R. (2014) Biobambam: tools for read pair collation based algorithms on BAM files. Source Code Biol Med. doi:10.1186/1751-0473-9-13
Garrison E, Marth, G. (2012) Haplotype-based variant detection from short-read sequencing. arXiv Preprint arXiv 1207:3907
Tan A, Abecasis GR, Kang HM (2015) Unified representation of genetic variants. Bioinformatics 31(13):2202–2204. doi:10.1093/bioinformatics/btv112
Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164. doi:10.1093/nar/gkq603
Ramsay AJ, Quesada V, Foronda M et al (2013) POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet 45(5):526–530. doi:10.1038/ng.2584
Hockemeyer D, Daniels JP, Takai H, de Lange T (2006) Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell 126(1):63–77. doi:10.1016/j.cell.2006.04.044
Bainbridge MN, Armstrong GN, Gramatges MM et al (2015) Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst 107(1):384. doi:10.1093/jnci/dju384
Calvete O, Martinez P, Garcia-Pavia P et al (2015) A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families. Nat Commun 6:8383. doi:10.1038/ncomms9383
Speedy HE, Kinnersley B, Chubb D et al (2016) Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. Blood. doi:10.1182/blood-2016-01-695692
Petr EJ, Else T (2016) Genetic predisposition to endocrine tumors: diagnosis, surveillance and challenges in care. Semin Oncol 43(5):582–590. doi:10.1053/j.seminoncol.2016.08.007
Siolek M, Cybulski C, Gasior-Perczak D et al (2015) CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer 137(3):548–552. doi:10.1002/ijc.29426
Rio Frio T, Bahubeshi A, Kanellopoulou C et al (2011) DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA 305(1):68–77. doi:10.1001/jama.2010.1910
Liu X, Bishop J, Shan Y et al (2013) Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20(4):603–610 doi:10.1530/ERC-13-0210
Acknowledgements
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA046592. TE is sponsored by the American Heart Association (14SDG17990000) and the NIH (1R01HL130106-01). We thank the University of Michigan DNA Sequencing Core for performing sequencing analysis. We are thankful to our patients in our registries allowing us to work with them clinically and in research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors do not have any conflict of interest pertinent to the submitted work.
Additional information
Tremika Le-Shan Wilson, Namita Hattangady and Antonio Marcondes Lerario have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Wilson, T.LS., Hattangady, N., Lerario, A.M. et al. A new POT1 germline mutation—expanding the spectrum of POT1-associated cancers. Familial Cancer 16, 561–566 (2017). https://doi.org/10.1007/s10689-017-9984-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-017-9984-y